RLAY — Relay Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1812364 ·
Last close
$16.47
Market Cap
$3.64B
52W High
$21.27
52W Low
$6.25
ADV30
2,540,519
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -90,245,000 | -81,745,000 | 901,692,000 | 124,184,000 | 82,696,000 |
| Jun 2026 | 350,000 | — | -90,824,000 | -83,707,000 | 967,457,000 | 121,189,000 | 77,448,000 |
| Mar 2026 | 3,000,000 | — | -78,590,000 | -73,291,000 | 699,613,000 | 204,589,000 | 57,430,000 |
| Dec 2025 | 7,000,000 | — | -60,630,000 | -54,890,000 | 621,331,000 | 84,018,000 | 54,271,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-214,020,000
Investing CF
$-222,292,000
Financing CF
$467,871,000
CapEx
$-411,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,253,512,000
Inventory
—
Receivables
—
ST Investments
$724,458,000
EBIT TTM
$-320,289,000
Pretax Income TTM
$-293,633,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,350,000
EBITDA
$-318,545,984
Free Cash Flow
$-117,454,624
Enterprise Value
$3,288,234,240
Total Cash
$848,641,984
Total Debt
$27,030,000
Shares Out
220,959,470
Trailing EPS
$-1.50
Book Value
$3.73
ROE
-41.2%
ROA
-25.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,355,000 | -302,738,000 | -276,479,000 | 621,331,000 | 54,271,000 | 567,060,000 | -235,455,000 |
| Dec 2024 | 10,007,000 | -385,674,000 | -337,708,000 | 871,296,000 | 93,504,000 | 777,792,000 | -249,107,000 |
| Dec 2023 | 25,546,000 | -379,422,000 | -341,973,000 | 843,980,000 | 91,977,000 | 752,003,000 | -300,316,000 |
| Dec 2022 | 1,381,000 | -310,952,000 | -290,509,000 | 1,099,771,000 | 149,553,000 | 950,218,000 | -229,490,000 |
TTM Snapshot
Revenues TTM
$10,349,000
NetIncome TTM
$-286,037,000
OpCashFlow TTM
—
Assets (Latest)
$967,457,000
Forward EPS
$-1.60
Max Pain — expiry 2026-12-18
max pain strike: $19.00 · spot: $16.51 · call oi: 8,870 · put oi: 7,423
Expected Move to 2026-12-18:
±$4.58
(27.71%) —
implied range
$11.94 –
$21.09
· ATM straddle on $17.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
| CRSP | CRISPR Therapeutics AG | $3.89B | $40.15 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
| VCEL | Vericel Corp | $2.95B | $57.88 | — |
News headlines (Yahoo Finance, 1h cache)
Relay Therapeutics (RLAY) Could Be 26% Undervalued After Third Quarter 2026 Results
2026-11-10 01:16 · Yahoo
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
2026-11-04 21:05 · Yahoo
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
2026-11-02 21:05 · Yahoo
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
2026-10-28 20:12 · Yahoo
Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
2026-10-08 06:12 · Yahoo
Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
2026-10-08 02:10 · Yahoo
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
2026-09-22 13:30 · Yahoo
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
2026-09-02 17:20 · Yahoo
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
2026-09-01 20:46 · Yahoo
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
2026-08-21 19:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.